David Bredt is CSO at Rapport Therapeutics, Inc. (RAPP). They have made 2 open-market trades across 1 company since 2025, most recently 2026-02-19.
CIK 0002022087
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RAPP | 393,075 | $10.8M |
Shares reported on the most recent Form 4, priced at the 2026-02-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RAPP | SELL | 2026-02-17 | 2026-02-19 | $29.02 | $247K | -6.2% | -6.0% | +20.5% |
| RAPP | SELL · 10b5-1 | 2026-01-15 | 2026-01-16 | $26.84 | $228K | +1.6% | +10.4% | +50.2% |
| RAPP | SELL | 2025-12-31 | 2026-01-05 | $30.05 | $197K | -2.8% | -4.4% | +17.1% |
| RAPP | SELL · 10b5-1 | 2025-12-15 | 2025-12-16 | $29.99 | $486K | -1.0% | -12.1% | -9.6% |
| RAPP | SELL · 10b5-1 | 2025-11-17 | 2025-11-18 | $25.19 | $428K | +10.3% | +14.5% | +12.2% |
| RAPP | SELL · 10b5-1 | 2025-10-15 | 2025-10-16 | $25.76 | $410K | +18.1% | +2.4% | +11.8% |
| RAPP | SELL · 10b5-1 | 2025-09-15 | 2025-09-17 | $24.19 | $411K | +7.4% | -4.1% | +18.1% |
| RAPP | SELL · 10b5-1 | 2025-08-15 | 2025-08-18 | $15.00 | $127K | +16.0% | +81.6% | +73.4% |
| RAPP | SELL · 10b5-1 | 2025-07-15 | 2025-07-16 | $14.00 | $119K | +8.4% | -4.8% | +61.1% |
| RAPP | SELL · 10b5-1 | 2025-06-16 | 2025-06-18 | $11.00 | $94K | +1.9% | +32.3% | +135.9% |
| RAPP | SELL · 10b5-1 | 2025-05-15 | 2025-05-19 | $9.56 | $81K | -18.0% | +9.3% | +44.6% |
| RAPP | SELL · 10b5-1 | 2025-04-15 | 2025-04-16 | $9.57 | $81K | +14.9% | +3.5% | +49.5% |
| RAPP | SELL · 10b5-1 | 2025-03-14 | 2025-03-17 | $10.85 | $92K | -4.8% | -4.2% | +9.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.